BMY, Acceleron Announce New Data From Reblozyl Phase 2 Trial For Adults With NTD Beta Thalassemia
NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) and Acceleron Pharma Inc. (XLRN) announced Friday the first data from the Phase 2 BEYOND study evaluating Reblozyl (luspatercept-aamt), a first-in-class